Plain language summary: tarlatamab for patients with previously treated small cell lung cancer Article Swipe
Related Concepts
Medicine
Lung cancer
Oncology
Cancer
Internal medicine
Myung‐Ju Ahn
,
Byoung Chul Cho
,
Enriqueta Felip
,
Ippokratis Korantzis
,
Kadoaki Ohashi
,
Margarita Majem
,
Óscar Juan
,
Sabin Handzhiev
,
Hiroki Izumi
,
Jong Seok Lee
,
Rafał Dziadziuszko
,
Jürgen Wolf
,
Fiona Blackhall
,
Martin Reck
,
Jean Bustamante Alvarez
,
Horst-Dieter Hummel
,
Anne‐Marie C. Dingemans
,
Jacob Sands
,
Hiroaki Akamatsu
,
Taofeek K. Owonikoko
,
Suresh S. Ramalingam
,
Hossein Borghaei
,
Melissa L. Johnson
,
Shuang Huang
,
Sujoy Mukherjee
,
Mukul Minocha
,
Tony Jiang
,
Pablo Martínez
,
Erik S. Anderson
,
Luis Paz‐Ares
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1080/14796694.2024.2402152
· OA: W4404275052
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1080/14796694.2024.2402152
· OA: W4404275052
The study found that tarlatamab given every 2 weeks shrank SCLC in participants with SCLC who received previous treatments. Participants given the 10 mg tarlatamab dose had fewer side effects than those given the 100 mg tarlatamab dose.<b>Clinical Trial Registration:</b> NCT05740566 (DeLLphi-304) (ClinicalTrials.gov).
Related Topics
Finding more related topics…